BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Acorda Therapeutics Inc.

Headquarters: Ardsley, NY, United States of America
Year Founded: 1995
Status: Public
Industry Sector: HealthTechnology
CEO: Ronald Cohen, MD
Number Of Employees: 102
Enterprise Value: $179,279,000
PE Ratio: 0
Exchange/Ticker 1: Pink:ACORQ
Exchange/Ticker 2: N/A
Latest Market Cap: $16,800

BioCentury | Jul 16, 2024
Deals

Deals report: Ipsen gets second ADC; Context buys MSLN

Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Apr 2, 2024
Deals

Entering bankruptcy, decades-old Acorda finds potential buyer in Merz

German company would gain rights to marketed drugs for $185M
BioCentury | May 16, 2023
Management Tracks

JLABS vet Calcagno becomes CBO of Vir

Plus: Therini names Frank Lee executive chair and updates from OMass, Sapir, Pan Cancer T, and more 
BioCentury | Mar 28, 2023
Management Tracks

New strategy heads at Genmab and Codagenix

Plus: OncoVerity names Colao CEO and Smith CMO, and updates from Silence, Mannkind, Immuneering and more
BioCentury | Feb 3, 2023
Product Development

Feb. 2 Quick Takes: Roche’s pipeline cuts include IPF therapy from Promedior deal

Plus Karuna licenses Goldfinch assets and updates from Vera, BioNTech, Ratio and more
BioCentury | Jul 11, 2022
Politics, Policy & Law

Biotech leaders assail CBO estimate

CEOs, investors, patients say CBO underestimates number of drugs that Medicare drug price bill would kill
BioCentury | Sep 11, 2021
Finance

Fred Frank, co-founder of the biotech industry, is dead at 89

His influence can be found on deals that built biopharma ecosystem
BioCentury | May 6, 2021
Politics, Policy & Law

As Biden backs WTO IP waiver for COVID vaccines, debate focuses on precedent, not access

The biopharma industry condemned, and a wide range of politicians and global health advocates praised, the Biden administration’s decision to support a WTO waiver of IP protections for COVID-19
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

President Biden nominated Chiquita Brooks-LaSure as CMS administrator. Brooks-LaSure previously served under the Obama administration as deputy director for policy at CMS’ Center for
BioCentury | Nov 4, 2020
Politics, Policy & Law

Warp Speed co-leader Slaoui signs letter supporting Fauci

Moncef Slaoui, chief scientific adviser to Operation Warp Speed, has signed a public letter expressing support for Anthony Fauci, director of NIH’s National Institutes of Allergy and Infectious
Items per page:
1 - 10 of 417
Help Center
Username
Request a Demo
Request Training
Ask a Question